PTEN and endometrial cancer: The presence of somatically acquired inactivating mutations and/or deletions of the PTEN tumor-suppressor gene in 30%–50% of sporadic endometrial carcinomas favors PI3K/Akt/mTOR signaling in endometrial cancer (Tashiro et al., 1997; Ali, 2000).